Tecemotide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tecemotide" in English language version.

refsWebsite

Global rank English rank

11oncothyreon.com

low place

low place

7merckgroup.com

low place

low place

3web.archive.org

1^st place

1^st place

2^nd place

2^nd place

2clinicaltrials.gov

5,225^th place

4,062^nd place

low place

low place

4^th place

4^th place

195^th place

302^nd place

1fiercevaccines.com

low place

low place

49^th place

47^th place

low place

low place

1patents.google.com

1,182^nd place

725^th place

abcsg.at

clinicaltrials.gov

doi.org

Wurz GT, Kao CJ, Wolf M, DeGregorio MW (2015-01-27). "Tecemotide: an antigen-specific cancer immunotherapy". Human Vaccines & Immunotherapeutics. 10 (11): 3383–3393. doi:10.4161/hv.29836. PMC 4514140. PMID 25483673.
Butts C (August 2007). "Stimuvax (L-BLP25): a peptide vaccine strategy in non-small cell lung cancer: M17-03". Journal of Thoracic Oncology. 2 (Supplement 4): S199–201. doi:10.1097/01.JTO.0000282977.65747.30.

fiercevaccines.com

Merck KGaA to test Stimuvax in breast cancer trial (FierceVaccines)

merckgroup.com

nih.gov

ncbi.nlm.nih.gov

Wurz GT, Kao CJ, Wolf M, DeGregorio MW (2015-01-27). "Tecemotide: an antigen-specific cancer immunotherapy". Human Vaccines & Immunotherapeutics. 10 (11): 3383–3393. doi:10.4161/hv.29836. PMC 4514140. PMID 25483673.

pubmed.ncbi.nlm.nih.gov

Wurz GT, Kao CJ, Wolf M, DeGregorio MW (2015-01-27). "Tecemotide: an antigen-specific cancer immunotherapy". Human Vaccines & Immunotherapeutics. 10 (11): 3383–3393. doi:10.4161/hv.29836. PMC 4514140. PMID 25483673.

oncothyreon.com

ir.oncothyreon.com

oncothyreon.com

Goss G, Anderson H, Maksymiuk A, Vergidis D, Soulieres D, Cormier Y, et al. (September 2009). "BLP25 liposome vaccine (L-BLP25): long-term safety results from a phase IIb study of patients with stage IIIB and IV non-small-cell lung cancer (NSCLC) treated for 2 years or more" (PDF). Journal of Thoracic Oncology. 4 (9). Philadelphia: Lippincott Williams & Wilkins: S681. Archived from the original (PDF) on 17 October 2014.

oncozine.com

Experimental Cancer Treatment L-BLP25 (Stimuvax) Did Not Meet Primary Endpoint of Improvement in Overall Survival in Pivotal Phase III Trial in Patients with Non-Small Cell Lung Cancer (Onco'Zine - The International Cancer Network)

patents.google.com

US Patent 6,600,012, Agrawal et al., Lipid-modified MUC-1 derivatives

reuters.com

UPDATE 2-Merck to test Stimuvax cancer drug in Phase III (Thomson Reuters)

web.archive.org

Goss G, Anderson H, Maksymiuk A, Vergidis D, Soulieres D, Cormier Y, et al. (September 2009). "BLP25 liposome vaccine (L-BLP25): long-term safety results from a phase IIb study of patients with stage IIIB and IV non-small-cell lung cancer (NSCLC) treated for 2 years or more" (PDF). Journal of Thoracic Oncology. 4 (9). Philadelphia: Lippincott Williams & Wilkins: S681. Archived from the original (PDF) on 17 October 2014.
Oncothyreon's 8-K SEC filing from Aug 18, 2014 Archived August 21, 2014, at the Wayback Machine
Oncothyreon's 8-K SEC filing from Aug 18, 2014

who.int

WHO Drug Information, Vol. 26, No. 4, 2012; Proposed INN: List 108